SEHK:9969Biotechs
InnoCare Pharma (SEHK:9969): Assessing Valuation After Landmark NTRK Solid-Tumor Approval for Zurletrectinib
InnoCare Pharma (SEHK:9969) just cleared a major milestone, with China’s regulator approving its next generation TRK inhibitor zurletrectinib for NTRK fusion positive solid tumors, the company’s first green light in solid cancers.
See our latest analysis for InnoCare Pharma.
The zurletrectinib approval lands after a volatile stretch, with InnoCare’s share price still up strongly this year thanks to a 150.79% year to date share price return. At the same time, the 90 day share price return of...